FDA Approves Every Eight-Week Dosing for Eli Lilly's EBGLYSS in Atopic Dermatitis
LLY sits 83% above its 52-week low of $623.78.
Summary
The FDA has approved a new, less frequent maintenance dosing regimen for Eli Lilly's EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, allowing for one dose every eight weeks. This approval provides patients with the option of as few as six injections per year, significantly improving convenience compared to the previously approved once-monthly schedule. This positive regulatory update enhances EBGLYSS's competitive profile in the dermatology market, potentially boosting patient adherence and market penetration for the drug. This follows a period of significant positive news for Eli Lilly, including the FDA approval of its weight-loss drug Foundayo and strong financial performance.
At the time of this announcement, LLY was trading at $1,143.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.